Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
70.11
Dollar change
-1.30
Percentage change
-1.82
%
IndexRUT P/E- EPS (ttm)-5.45 Insider Own3.66% Shs Outstand101.64M Perf Week6.18%
Market Cap7.22B Forward P/E- EPS next Y-3.21 Insider Trans-5.83% Shs Float99.23M Perf Month-4.08%
Income-526.24M PEG- EPS next Q-1.14 Inst Own109.87% Short Float14.91% Perf Quarter-15.98%
Sales7.53M P/S959.01 EPS this Y18.14% Inst Trans-1.40% Short Ratio4.06 Perf Half Y134.32%
Book/sh-3.80 P/B- EPS next Y28.05% ROA-57.23% Short Interest14.80M Perf Year100.43%
Cash/sh5.97 P/C11.74 EPS next 5Y15.00% ROE-572.15% 52W Range25.98 - 110.25 Perf YTD-16.03%
Dividend Est.- P/FCF- EPS past 5Y-22.79% ROI-154.11% 52W High-36.41% Beta0.68
Dividend TTM- Quick Ratio6.12 Sales past 5Y12.30% Gross Margin-82.78% 52W Low169.86% ATR (14)3.62
Dividend Ex-Date- Current Ratio6.12 EPS Y/Y TTM-28.21% Oper. Margin-6589.71% RSI (14)51.02 Volatility4.94% 5.12%
Employees423 Debt/Eq- Sales Y/Y TTM-92.04% Profit Margin-6988.63% Recom1.44 Target Price96.65
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q4.77% Payout- Rel Volume0.44 Prev Close71.41
Sales Surprise-78.05% EPS Surprise-43.97% Sales Q/Q-14.56% EarningsFeb 27 AMC Avg Volume3.64M Price70.11
SMA204.27% SMA50-6.06% SMA20047.37% Trades Volume1,611,905 Change-1.82%
Date Action Analyst Rating Change Price Target Change
Jan-24-24Downgrade UBS Buy → Neutral $61 → $92
Jan-05-24Downgrade Morgan Stanley Overweight → Equal-Weight $60 → $90
Nov-09-23Initiated Goldman Buy $50
Nov-07-23Initiated B. Riley Securities Buy $66
Aug-15-23Initiated SVB Securities Outperform $58
Feb-17-23Initiated BofA Securities Neutral $49
Dec-23-22Reiterated Needham Buy $60 → $58
Dec-20-22Initiated Truist Buy $60
Oct-11-22Initiated UBS Buy $80
Jan-28-22Initiated Goldman Buy $74
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
06:46AM Loading…
Mar-12-24 06:46AM
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM Loading…
04:17PM
04:00PM
Feb-13-24 04:00PM
Feb-12-24 12:38AM
Feb-09-24 10:01AM
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
04:22PM Loading…
Jan-11-24 04:22PM
04:05PM
12:58PM
12:54PM
12:47PM
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
04:42PM
02:12PM
01:11PM
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
02:43PM
09:44AM
Dec-27-23 05:26PM
03:52PM
01:59PM
01:00PM
12:21PM
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Sep-14-23 01:02AM
Sep-09-23 03:59PM
Sep-07-23 04:29PM
04:00PM
Sep-06-23 07:30AM
Sep-01-23 04:00PM
Aug-08-23 06:20AM
Aug-03-23 05:15PM
04:11PM
04:00PM
Aug-01-23 04:00PM
Jul-27-23 04:00PM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malik Fady IbrahamEVP Research & DevelopmentMar 05 '24Option Exercise6.6728,604190,789167,577Mar 05 04:05 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 05 '24Sale67.5632,6042,202,606138,973Mar 05 04:05 PM
HENDERSON JOHN TDirectorFeb 14 '24Option Exercise4.445,00022,20047,632Feb 14 04:04 PM
HENDERSON JOHN TDirectorFeb 14 '24Sale76.485,000382,40042,632Feb 14 04:04 PM
Blum Robert IPresident & CEOFeb 13 '24Option Exercise6.6712,50083,375454,297Feb 13 04:01 PM
Blum Robert IPresident & CEOFeb 13 '24Sale76.8512,500960,625441,797Feb 13 04:01 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 06 '24Option Exercise6.6728,605190,795175,578Feb 06 04:43 PM
Malik Fady IbrahamEVP Research & DevelopmentFeb 06 '24Sale79.3032,6052,585,496142,973Feb 06 04:43 PM
Blum Robert IPresident & CEOJan 31 '24Option Exercise6.6712,50083,375454,297Feb 02 04:41 PM
Blum Robert IPresident & CEOJan 31 '24Sale79.5712,500994,625441,797Feb 02 04:41 PM
Blum Robert IPresident & CEOJan 19 '24Option Exercise6.6712,50083,375454,297Jan 22 05:19 PM
Blum Robert IPresident & CEOJan 19 '24Sale81.4212,5001,017,750441,797Jan 22 05:19 PM
HENDERSON JOHN TDirectorJan 12 '24Option Exercise4.445,00022,20047,632Jan 12 05:20 PM
HENDERSON JOHN TDirectorJan 12 '24Sale85.145,000425,70042,632Jan 12 05:20 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 04 '24Option Exercise7.9611,67892,957162,651Jan 04 04:36 PM
Malik Fady IbrahamEVP Research & DevelopmentJan 04 '24Sale86.9815,6781,363,712146,973Jan 04 04:36 PM
Blum Robert IPresident & CEOJan 02 '24Option Exercise6.6712,50083,375454,297Jan 02 05:55 PM
Blum Robert IPresident & CEOJan 02 '24Sale85.0812,5001,063,500441,797Jan 02 05:55 PM
WIERENGA WENDALLDirectorDec 27 '23Option Exercise4.4410,00044,40023,653Dec 27 04:11 PM
WIERENGA WENDALLDirectorDec 27 '23Sale73.6010,000736,00018,653Dec 27 04:11 PM
HENDERSON JOHN TDirectorDec 18 '23Option Exercise6.7213,02087,49444,838Dec 19 04:12 PM
Blum Robert IPresident & CEODec 18 '23Option Exercise6.6712,50083,375454,297Dec 19 04:13 PM
Blum Robert IPresident & CEODec 18 '23Sale36.9512,500461,875441,797Dec 19 04:13 PM
HENDERSON JOHN TDirectorDec 18 '23Sale36.342,45889,32442,380Dec 19 04:12 PM
Blum Robert IPresident & CEONov 30 '23Option Exercise6.6712,50083,375453,917Dec 01 04:15 PM
Blum Robert IPresident & CEONov 30 '23Sale32.9912,500412,375441,417Dec 01 04:15 PM
Blum Robert IPresident & CEONov 15 '23Option Exercise6.6712,50083,375453,917Nov 15 05:22 PM
Blum Robert IPresident & CEONov 15 '23Sale34.5712,500432,125441,417Nov 15 05:22 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 09 '23Sale35.402,50088,500150,664Nov 09 04:35 PM
Blum Robert IPresident & CEOOct 30 '23Option Exercise6.6712,50083,375453,917Oct 30 04:02 PM
Blum Robert IPresident & CEOOct 30 '23Sale32.1712,500402,125441,417Oct 30 04:02 PM
Blum Robert IPresident & CEOOct 16 '23Option Exercise6.6712,50083,375453,917Oct 16 05:57 PM
Blum Robert IPresident & CEOOct 16 '23Sale33.7012,500421,250441,417Oct 16 05:57 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 12 '23Sale35.892,50089,725153,164Oct 12 06:39 PM
Blum Robert IPresident & CEOOct 06 '23Option Exercise6.6712,50083,375453,917Oct 06 04:52 PM
Blum Robert IPresident & CEOOct 06 '23Sale30.0012,500375,000441,417Oct 06 04:52 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 14 '23Sale34.862,50087,150155,664Sep 14 04:09 PM
Blum Robert IPresident & CEOSep 13 '23Option Exercise6.6712,50083,375453,917Sep 13 04:09 PM
Blum Robert IPresident & CEOSep 13 '23Sale34.9012,500436,206441,417Sep 13 04:09 PM
Blum Robert IPresident & CEOAug 25 '23Option Exercise7.7012,50096,275453,917Aug 28 06:45 PM
Blum Robert IPresident & CEOAug 25 '23Sale33.9912,500424,875441,417Aug 28 06:45 PM
WIERENGA WENDALLDirectorAug 21 '23Option Exercise6.726,02040,45424,225Aug 21 04:01 PM
WIERENGA WENDALLDirectorAug 21 '23Sale32.026,020192,76018,205Aug 21 04:01 PM
Blum Robert IPresident & CEOAug 11 '23Option Exercise9.5412,500119,287453,125Aug 11 04:18 PM
Blum Robert IPresident & CEOAug 11 '23Sale32.3712,500404,589441,417Aug 11 04:18 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 10 '23Sale31.702,50079,250158,164Aug 10 04:14 PM
Blum Robert IPresident & CEOAug 01 '23Option Exercise9.6512,500120,625452,108Aug 01 04:57 PM
Blum Robert IPresident & CEOAug 01 '23Sale32.6312,500407,856441,417Aug 01 04:57 PM
Blum Robert IPresident & CEOJul 13 '23Option Exercise9.6512,500120,625453,917Jul 13 04:10 PM
Blum Robert IPresident & CEOJul 13 '23Sale35.2812,500440,940441,417Jul 13 04:10 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 13 '23Sale35.372,50088,425160,664Jul 13 04:09 PM
Bhanji MunaDirectorJul 07 '23Sale34.122,00068,23514,031Jul 07 04:17 PM
Blum Robert IPresident & CEOJul 03 '23Option Exercise9.6512,500120,625453,917Jul 05 04:18 PM
Blum Robert IPresident & CEOJul 03 '23Sale32.6012,500407,500441,417Jul 05 04:18 PM
Blum Robert IPresident & CEOJun 12 '23Option Exercise9.6512,500120,625453,917Jun 12 05:49 PM
Blum Robert IPresident & CEOJun 12 '23Sale37.0612,500463,250441,417Jun 12 05:49 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 08 '23Sale38.072,50095,175163,164Jun 08 04:31 PM
Blum Robert IPresident & CEOMay 31 '23Option Exercise9.6512,500120,625453,558Jun 01 05:06 PM
Blum Robert IPresident & CEOMay 31 '23Sale37.6712,500470,875441,058Jun 01 05:06 PM
Blum Robert IPresident & CEOMay 16 '23Option Exercise9.6512,500120,625453,558May 16 04:33 PM
Blum Robert IPresident & CEOMay 16 '23Sale37.4112,500467,625441,058May 16 04:33 PM
HENDERSON JOHN TDirectorMay 15 '23Option Exercise6.784,16628,24529,586May 15 04:07 PM
HENDERSON JOHN TDirectorMay 15 '23Sale37.774,166157,35025,420May 15 04:07 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 11 '23Sale39.501,78770,586165,396May 11 05:26 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 03 '23Option Exercise7.967,00055,720174,183May 03 04:46 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 03 '23Sale40.007,000280,000167,183May 03 04:46 PM
Blum Robert IPresident & CEOApr 28 '23Option Exercise9.6512,500120,625453,558Apr 28 04:01 PM
Blum Robert IPresident & CEOApr 28 '23Sale37.6812,500471,000441,058Apr 28 04:01 PM
Blum Robert IPresident & CEOApr 14 '23Option Exercise9.6512,500120,625453,558Apr 14 06:34 PM
Blum Robert IPresident & CEOApr 14 '23Sale35.6112,500445,125441,058Apr 14 06:34 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 13 '23Sale34.214,000136,840167,183Apr 13 04:49 PM